- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stephen Silberstein Discusses Erenumab Use for Menstrual Migraine
If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
Transcript:
The American Journal of Managed Care®(AJMC®): Results from STRIVE found erenumab is a safe and effective option for treating menstrual migraine. Do you think erenumab will be indicated for this condition in the near future?
Dr. Silberstein: There are 2 types of menstrual migraine. There's pure menstrual migraine when women only have migraine with their period and there's menstrual migraine that occurs at any other time. So if you only have migraine with your period for a couple days, I think it would be difficult to recommend taking a drug all the time just for a headache that only occurs 3 days a month. If you have menstrual migraine plus other migraine, and it's intractable, obviously, they should get treatment. There are other treatment options, short-term treatment options, for hormonal treatment for women with pure menstrual migraine.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
